share_log

Asensus Surgical Announces St. Marianna University School of Medicine Yokohama City Seibu Hospital in Japan to Initiate Senhance Surgery Program

Asensus Surgical Announces St. Marianna University School of Medicine Yokohama City Seibu Hospital in Japan to Initiate Senhance Surgery Program

Asensus Surgical宣佈日本聖瑪麗安娜大學醫學院橫濱西部醫院將啓動Senhance手術項目。
Asensus Surgical ·  06/24 00:00

RESEARCH TRIANGLE PARK, N.C., June 24, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, today announced that St. Marianna University School of Medicine Yokohama City Seibu Hospital in Japan has entered into an agreement to lease and utilize a Senhance Surgical System in the Urology and Gastroenterology/General Surgery department.

2024年6月24日,北卡羅來納州研究三角公園(GLOBE NEWSWIRE)--Asensus Surgical,Inc. (紐交所: ASXC),一家數字化外科醫生和患者之間接口的醫療器械公司,今天宣佈,日本聖瑪麗安娜大學醫學院橫濱市西部醫院已經簽署一份協議,租賃和利用Senhance手術系統進行泌尿外科和腸胃/普外科的手術。

"We are excited to collaborate with the St. Marianna University School of Medicine Yokohama City Seibu Hospital to bring our Senhance Surgical System to this innovative institution," said Anthony Fernando, President and CEO of Asensus Surgical. "Powered by our Intelligent Surgical Unit with Augmented Intelligence capabilities, this system represents a leap forward, offering surgeons unparalleled real-time insights that leverage the collective expertise from procedures performed around the world."

“我們很高興與聖瑪麗安娜大學醫學院橫濱市西部醫院合作,將我們的Senhance手術系統帶到這個創新機構,” Asensus Surgical總裁兼首席執行官安東尼·費爾南多(Anthony Fernando)表示。 “由我們的智能手術單元驅動,並具有增強智能功能,這個系統代表了一次飛躍,爲外科醫生提供了無與倫比的實時見解,利用了全球範圍內執行的手術的集體專業知識。”

"The Senhance System's ability to facilitate a seamless integration of human skill with clinical intelligence will be tremendously valuable for our surgeons," said Dr. Masanori Naito, M.D.,Ph.D. Hospital Vice Director, Head of Gastroenterological & General Surgery. "Our hospital seeks to blend scientific excellence with compassionate, patient-centered care. We look forward to harnessing its capabilities in our GI/General Surgery & Urology specialties as we continue pushing the boundaries of medical innovation."

“Senhance系統的能力,將人類技能與臨床智能無縫集成,對我們的外科醫生將是極其有價值的,”  橫濱市西部醫院胃腸肝膽外科、普通外科主任、醫學博士內藤正則醫師表示。 “我們的醫院尋求將科學卓越與熱情和以患者爲中心的護理相融合。 我們期待在GI/普外科和泌尿科領域發揮其功能,繼續推動醫療創新的邊界。”

Senhance Surgical System

The Senhance Surgical System is designed to increase surgeon control and reduce variability through Augmented Intelligence and deep learning capabilities.

Senhance手術系統旨在通過增強智能和深度學習功能,提高外科醫生的控制力和降低可變性。

About St. Marianna University School of Medicine Yokohama City Seibu Hospital

關於聖瑪麗安娜大學醫學院橫濱市西部醫院

Our university was founded in 1971 by the devout Catholic Dr. Kamon Akashi. Then-Pope Paul VI took a great interest in the university's establishment and presented the special gift of a chalice and paten to mark the occasion. Japan's only medical university with Christian ideals as its founding ethos, our university has so far trained nearly 5,000 physicians filled with the spirit of love and dedicated service. This philosophy—the Marianna Spirit—is reflected not only in the undergraduate educational curriculum but also throughout the care offered at our associated medical facilities and in our specialist postgraduate education and research. It forms the very foundation of our outstanding education, which produces individuals who are both proficient scientists and compassionate physicians. St. Marianna University School of Medicine Yokohama City Seibu Hospital opened in 1987 as part of the Yokohama 21st Century Plan. It is a sophisticated general hospital for the 21st century that actively incorporates the very latest medical care techniques. It also has a tertiary emergency care center capable of dealing with all fields of medicine around the clock.

聖瑪麗安娜大學醫學院於1971年由虔誠的天主教徒赤司鴨門博士創立,時任教皇保羅六世對該大學的建立非常感興趣,併爲了紀念此事獻上了特殊禮物——聖盃和典禮用盤。作爲日本惟一將基督教理念作爲創立精神的醫學院,我們的大學迄今爲止已培養了近5,000名充滿愛和奉獻服務精神的醫生。 這種哲學——聖瑪麗安娜精神不僅體現在本科教育課程中,而且貫穿於我們相關的醫療設施的護理以及我們的專業研究生教育和研究中。它構成了我們傑出教育的基礎,培養出既精通科學的科學家,又具備同情心的醫生。聖瑪麗安娜大學醫學院於1987年作爲橫濱21世紀計劃的一部分開設,是21世紀的先進綜合醫院,積極融合最新的醫療技術,同時還擁有可全天候應對各種醫學領域的三級急診護理中心。

About Asensus Surgical, Inc.

關於Asensus Surgical, Inc.

Asensus Surgical is revolutionizing surgery with the first intra-operative Augmented Intelligence technology approved for use in operating rooms around the world. Recognized as an award-winning leader in digital technology, Asensus is committed to making surgery more accessible and predictable while delivering consistently superior outcomes. The Company's novel approach to digitizing laparoscopy has led to system placements globally. Led by engineers, medical professionals, and industry luminaries, Asensus is powered by human ingenuity and driven by collaboration. To learn more about Asensus, visit www.asensus.com.

Asensus Surgical正在革新手術領域,開發首個已獲批在全球手術室使用的術中增強智能技術。作爲數字技術的獲獎領導者,Asensus致力於使手術更加易於接近和可預測,並提供持續優越的結果。該公司對腹腔鏡手術的數字化方法已經在全球範圍內得到應用。Asensus由工程師、醫療專業人士和行業權威人士領導,以人類智慧爲動力,以協作爲驅動力。要了解更多關於Asensus的信息,請訪問www.asensus.com.

Follow Asensus

關注Asensus

Forward-Looking Statements

前瞻性聲明

This press release includes statements relating to the Senhance Surgical System and St. Marianna University School of Medicine Yokohama City Seibu Hospital in Japan initiating a program with the Senhance System. These statements and other statements regarding our future plans and goals constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include whether Asensus Surgical can accelerate the adoption of the Senhance Surgical System throughout Japan and other key geographies around the world and whether the Senhance Surgical System will enable St. Marianna University School of Medicine Yokohama City Seibu Hospital to offer surgeons unparalleled real-time insights that leverage the collective expertise from procedures performed around the world. For a discussion of the risks and uncertainties associated with the Company's business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 22, 2024 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

本新聞發稿涉及Senhance手術系統和聖瑪麗安娜大學醫學院橫濱市西部醫院啓動Senhance System計劃。這些聲明和其他關於我們未來計劃和目標的聲明構成了《1933年證券法》第27A條和《1934年證券交易法》第21E條(以下簡稱“法案”)中的“前瞻性聲明”,並旨在獲得1995年制定的私人證券訴訟改革法案的責任免除保護。此類聲明可能面臨難以預測、超出我們控制範圍的風險和不確定因素,可能導致結果與期望有所不同,幷包括Asensus Surgical能否加速在日本和其他關鍵地理位置推廣Senhance手術系統,以及Senhance手術系統是否能夠使聖瑪麗安娜大學醫學院橫濱市西部醫院爲外科醫生提供不可比擬的實時見解,利用全球執行的手術的集體專業知識。有關公司業務風險和不確定性的討論,請查看我們向證券交易委員會(SEC)提交的備案文件,包括我們於2024年3月22日向SEC提交的年報《10-K表格》,以及我們的其他提交給SEC的文件。請勿過度依賴這些前瞻性聲明,這些聲明基於本新聞發稿日期的預期,並僅從本新聞發稿日期起發表。我們無義務公開更新或修正任何前瞻性聲明,無論是由於新信息、未來事項或其他原因。

INVESTOR CONTACT:

投資者聯繫方式:

Mark Klausner or Mike Vallie
ICR Westwicke
invest@asensus.com
443-213-0499

Mark Klausner或Mike Vallie
ICR Westwicke
invest@asensus.com
443-213-0499

MEDIA CONTACT:
Dan Ventresca
Matter Communications
AsensusPR@matternow.com
617-874-5488

媒體聯繫人:
Dan Ventresca
Matter Communications
AsensusPR@matternow.com
617-874-5488

Primary Logo

Senhance Surgical System
Senhance手術系統
big
The Senhance Surgical System is designed to increase surgeon control and reduce variability through Augmented Intelligence and deep learning capabilities.
Senhance手術系統旨在通過增強智能和深度學習功能,提高外科醫生的控制力和降低可變性。

Source: Asensus Surgical, Inc.

來源:Asensus Surgical,Inc。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論